ProPhase Labs Files 8-K on Financials and Operations
Ticker: PRPH · Form: 8-K · Filed: Mar 15, 2024 · CIK: 868278
| Field | Detail |
|---|---|
| Company | Prophase Labs, INC. (PRPH) |
| Form Type | 8-K |
| Filed Date | Mar 15, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0005 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, operations, sec-filing
TL;DR
ProPhase Labs dropped an 8-K on March 15th detailing their financials and operations - check it out!
AI Summary
ProPhase Labs, Inc. filed an 8-K on March 15, 2024, reporting on its results of operations and financial condition. The filing also includes information related to Regulation FD disclosure and financial statements and exhibits. The company, formerly known as Quigley Corp, is incorporated in Delaware and headquartered in Garden City, New York.
Why It Matters
This 8-K filing provides crucial updates on ProPhase Labs' financial performance and operational status, which are essential for investors to assess the company's current health and future prospects.
Risk Assessment
Risk Level: low — This filing is a standard 8-K reporting routine financial and operational information, not indicating any immediate or unusual risks.
Key Players & Entities
- ProPhase Labs, Inc. (company) — Filer
- Quigley Corp (company) — Former Company Name
- March 15, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Garden City, New York (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for ProPhase Labs, Inc.?
The primary purpose of this 8-K filing is to report on the Company's Results of Operations and Financial Condition, as well as provide Regulation FD Disclosure and Financial Statements and Exhibits.
When was this 8-K report filed?
This 8-K report was filed on March 15, 2024.
What was ProPhase Labs, Inc. formerly known as?
ProPhase Labs, Inc. was formerly known as Quigley Corp.
In which state is ProPhase Labs, Inc. incorporated?
ProPhase Labs, Inc. is incorporated in Delaware.
What is the address of ProPhase Labs, Inc.'s principal executive offices?
The address of ProPhase Labs, Inc.'s principal executive offices is 711 Stewart Avenue, Suite 200, Garden City, New York 11530.
Filing Stats: 526 words · 2 min read · ~2 pages · Grade level 9.5 · Accepted 2024-03-15 08:00:25
Key Financial Figures
- $0.0005 — ch Registered Common Stock, par value $0.0005 PRPH Nasdaq Capital Market Indic
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex99-1.htm (EX-99.1) — 177KB
- 0001493152-24-010013.txt ( ) — 410KB
- prph-20240315.xsd (EX-101.SCH) — 3KB
- prph-20240315_lab.xml (EX-101.LAB) — 33KB
- prph-20240315_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2024 PROPHASE LABS, INC. (Exact name of Company as specified in its charter) Delaware 000-21617 23-2577138 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 711 Stewart Avenue , Suite 200 Garden 11530 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (215) 345-0919 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions ( see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities Registered Pursuant to Section 12(b) of the Exchange Act: Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Common Stock, par value $0.0005 PRPH Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 2.02 Results of Operations and Financial Condition. On March 15, 2024, ProPhase Labs, Inc. (the "Company") issued a press release announcing its financial results for the year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. Item 7.01 Regulation FD. As previously announced, the Company will conduct a conference call today, Friday, March 15, 2024, at 11:00 a.m. (Eastern Time) to discuss its financial results and provide an update on corporate developments. The information included in Items 2.02 and 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any registration therein. Item 9.01 Financial Statements and Exhibits. (d) Exhibits No. Description 99.1 Press Release dated March 15, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ProPhase Labs, Inc. By: /s/ Ted Karkus Ted Karkus Chairman of the Board and Chief Executive Officer Date: March 15, 2024